Caries presence in primary teeth · For interventions, pregnant women, mothers or other caregivers of infants in the first year of life; for outcomes, children up to 6 years…
It is very uncertain whether dietary advice on how to achieve a healthy diet for infants… changes caries presence in primary teeth compared with standard care (very low certainty).
1 finding from 1 review
Dental caries · For interventions, pregnant women, mothers or other caregivers of infants in the first year of life; for outcomes, children up to 6 years…
The review found no eligible studies for this question.
2 findings from 1 review
Overjet · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Reverse Forsus led to higher overjet compared with untreated control (no treatment); GRADE not reported.
1 finding from 1 review
ANB · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Chin cup (600 g force) showed no clear difference in ANB compared with chin cup (300 g force); GRADE not reported.
1 finding from 1 review
Perceived need for surgery in adulthood · Children and adolescents (aged 16 years or younger) with prominent lower front teeth (Class III malocclusion)
Facemask may leads to higher perceived need for surgery in adulthood compared with untreated control (no treatment) (low certainty).
1 finding from 1 review
Mother caries (dmfs increment) · For interventions, pregnant women and mothers of infants in the first year of life; for outcomes, children up to 6 years of age
Prophylaxis (teeth cleaning) and CHX or iodine-NaF solution… showed no clear difference in mother caries (dmfs increment) compared with placebo; GRADE not reported.
1 finding from 1 review
QoL · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Survival Log‐rank analysis Study enrolment to last date of · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Adverse events NRS (scale from 0 to 10; lower score = less toxicity) · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Quality of life · adults aged 18 years and older receiving palliative care
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival Cox regression model Study enrolment to last date of · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Adverse events Participant events · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
DeathClinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Systemic adverse events at · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).
1 finding from 1 review